Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091371 | 0.83 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14274485 | 0.83 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11350134 | 0.83 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4449040 | 0.82 | TAS1R3 (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2306741 | 0.82 | KMT2A (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| Fluoride SCHEMBL11786773 | 0.82 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2091369 | 0.82 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL23797876 | 0.80 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5932331 | 0.80 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11786768 | 0.80 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7618984-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-0426717-A1 | OPTICAL MEMORY. | RIEDEL DE HAEN AG (DE) | 1991-05-15 | — | — | EP | disclosed |
| WO-1990001480-A1 | OPTICAL MEMORY | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1990-02-22 | — | — | WO | disclosed |
| US-4618610-A | Triazine derivatives, and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-21 | — | — | US | disclosed |
| EP-0123254-A1 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093789-A1 | SULFONAMIDE COMPOUND | AKT1, ROCK1, ROCK2 | MEN1 2544/4885KMT2A 1671/4885SMN1; SMN2 2232/4885 |
| US-20070179127-A1 | Sulfonamide compound | MYLK, MYLK2, MYLK3 | MEN1 2620/4885KMT2A 1702/4885SMN1; SMN2 803/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | MEN1 2880/4885KMT2A 1754/4885SMN1; SMN2 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.